11
Participants
Start Date
March 11, 2004
Primary Completion Date
September 15, 2024
Study Completion Date
October 15, 2024
therapeutic estradiol
0.35mg/100ul per day as a nasal spray
deslorelin
1mg/100ul per day as a nasal spray
therapeutic testosterone
0.275mg/100ul per day as a nasal spray
therapeutic conventional surgery
Undergo risk reduction mastectomy
active surveillance
Undergo continued surveillance
quality-of-life assessment
Ancillary studies
laboratory biomarker analysis
Correlative studies
City of Hope Medical Center, Duarte
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER